KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

被引：0
|
作者：
F Loupakis
A Ruzzo
C Cremolini
B Vincenzi
L Salvatore
D Santini
G Masi
I Stasi
E Canestrari
E Rulli
I Floriani
K Bencardino
N Galluccio
V Catalano
G Tonini
M Magnani
G Fontanini
F Basolo
A Falcone
F Graziano
机构：
[1] Unit of Medical Oncology 2,Istituto Toscano Tumori and Department of Oncology
[2] Azienda-Ospedaliero Universitaria Pisana,Department of Biomolecular Sciences
[3] Transplantes and New Technologies in Medicine,Division of Pathology, Department of Surgery
[4] University of Pisa,undefined
[5] Section of Biochemistry and Molecular Biology “G. Fornaini”,undefined
[6] University of Urbino,undefined
[7] Unit of Medical Oncology,undefined
[8] University Campus Biomedico,undefined
[9] Via Alvaro del Portillo 200 – 00128 Rome,undefined
[10] Italy,undefined
[11] Mario Negri Institute for Pharmacological Research,undefined
[12] Via La Masa 19 – 20156 Milan,undefined
[13] Italy,undefined
[14] Unit of Medical Oncology,undefined
[15] San Raffaele Scientific Institute,undefined
[16] Via Olgettina 60 – 20132 Milan,undefined
[17] Italy,undefined
[18] Unit of Medical Oncology,undefined
[19] Hospital of Pesaro,undefined
[20] Via Lombroso 1 – 61100 Pesaro,undefined
[21] Italy,undefined
[22] University of Pisa,undefined
[23] Istituto Toscano Tumori,undefined
[24] Via Roma 67 – Pisa,undefined
[25] Italy,undefined
来源：
British Journal of Cancer | 2009年 / 101卷
关键词：
colorectal cancer; cetuximab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：715 / 721
页数：6
相关论文
共 50 条
  • [31] Mutations in NRAS codon 61, KRAS codon 146, and BRAF V600E as prognostic factors in patients who received anti-EGFR antibody for metastatic colorectal cancer.
    Takahashi, Naoki
    Yamada, Yasuhide
    Taniguchi, Hirokazu
    Akiyoshi, Kohei
    Honma, Yoshitaka
    Iwasa, Satoru
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Sensitive and selective detections of codon 12 and 13 KRAS mutations in a single tube using modified wild-type blocker
    Su, Ning
    Wei, Kun
    Zhao, Na
    Wang, Liu
    Duan, Guang-Jie
    Ren, Xiao-Dong
    Qu, Xue-Mei
    Huang, Qing
    CLINICA CHIMICA ACTA, 2019, 494 : 123 - 131
  • [33] MUTATIONS IN NRAS CODON 61 AND KRAS CODON 146 ARE POOR PROGNOSTIC FACTORS IN PATIENTS WHO RECEIVED ANTI-EGFR MONOCLONAL ANTIBODY FOR METASTATIC COLORECTAL CANCER
    Takahashi, N.
    Yamada, Y.
    Taniguchi, H.
    Honma, Y.
    Iwasa, S.
    Kato, K.
    Hamaguchi, T.
    Shimada, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 529 - 529
  • [34] MUTATIONS IN NRAS CODON 61 AND KRAS CODON 146 ARE POOR PROGNOSTIC FACTORS IN PATIENTS WHO RECEIVED ANTI-EGFR MONOCLONAL ANTIBODY FOR METASTATIC COLORECTAL CANCER
    Takahashi, N.
    Yamada, Y.
    Taniguchi, H.
    Akiyoshi, K.
    Honma, Y.
    Iwasa, S.
    Kato, K.
    Hamaguchi, T.
    Shimada, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 119 - 119
  • [35] Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients
    Terazawa, Tetsuji
    Nishitani, Hitoshi
    Kato, Ken
    Hashimoto, Hironobu
    Akiyoshi, Kohei
    Ito, Yuriko
    Nakamoto, Akihiro
    Iwasa, Satoru
    Nakajima, Takako Eguchi
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) : E132 - E137
  • [36] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Shitara, Kohei
    Yokota, Tomoya
    Takahari, Daisuke
    Shibata, Takashi
    Ura, Takashi
    Utsunomiya, Setsuo
    Inaba, Yoshitaka
    Yamaura, Hidekazu
    Sato, Yozo
    Najima, Mina
    Kawai, Hiroki
    Tajika, Masahiro
    Sawaki, Akira
    Yatabe, Yasushi
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (04) : 688 - 693
  • [37] PanitumumabIn Metastatic Colorectal Cancer with Wild-Type KRAS
    Juliane Weber
    Paul L. McCormack
    BioDrugs, 2008, 22 : 403 - 411
  • [38] Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
    Imamura, Yu
    Morikawa, Teppei
    Liao, Xiaoyun
    Lochhead, Paul
    Kuchiba, Aya
    Yamauchi, Mai
    Qian, Zhi Rong
    Nishihara, Reiko
    Meyerhardt, Jeffrey A.
    Haigis, Kevin M.
    Fuchs, Charles S.
    Ogino, Shuji
    CLINICAL CANCER RESEARCH, 2012, 18 (17) : 4753 - 4763
  • [39] Cetuximab/Irinotecan-Chemotherapy in KRAS Wild-type Pretreated Metastatic Colorectal Cancer: A Pooled Analysis and Review of Literature
    Barni, Sandro
    Ghilardi, Mara
    Borgonovo, Karen
    Cabiddu, Mary
    Zaniboni, Alberto
    Petrelli, Fausto
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (02) : 101 - 109
  • [40] Phase II study of combination chemotherapy with irinotecan and cetuximab for pretreated metastatic colorectal cancer harboring wild-type KRAS
    Kohei Shitara
    Tomoya Yokota
    Daisuke Takahari
    Takashi Shibata
    Takashi Ura
    Setsuo Utsunomiya
    Yoshitaka Inaba
    Hidekazu Yamaura
    Yozo Sato
    Mina Najima
    Hiroki Kawai
    Masahiro Tajika
    Akira Sawaki
    Yasushi Yatabe
    Kei Muro
    Investigational New Drugs, 2011, 29 : 688 - 693
12345